Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group

Katje Kleyer, Michael Schuendeln, Stephanie Sendker, Lina Marie Hoffmeister, Markus Schneider, Nils Von Neuhoff, Jan-Henning Klusmann, Dirk Reinhardt, Evangelia Antoniou

Blood (2025) 146 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2025-3403

Published: 2025

Journal Articles

Single-cell tracing of myeloid leukemia evolution in down syndrome reveals a latent progenitor bridging disease onset, progression and relapse

Stephanie Frenz-Wiessner, Yue Wang, Katja Rohde, Giovanni Quinones-Valdez, Hasan Issa, José Gonçalves-Dias, Konstantin Schuschel, Paul Mack, Meng-Wei Ko, Yuanyuan Wang, Feiyang Ma, Kathleen Sakamoto, Vivian Chang, Xinshu Xiao, Jan-Henning Klusmann, Hanna Mikkola

Blood (2025) 146 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2025-1472

Published: 2025

Journal Articles

Wildtype NUP98 cooperates with NPM1c to drive oncogenic transcription

Sara Gama, Marcel Müller, Hannah González Dammers, Elena Haarer, Sara Peruzzi, José Gonçalves-Dias, Jan-Henning Klusmann, Lu Yang, Renee Chen, Chun-Wei Chen, Stamatis Papathanasiou, Brunangelo Falini, Lorenzo Brunetti, Hannah Uckelmann

Blood (2025) 146 (Supplement 1): 865.

https://doi.org/10.1182/blood-2025-865

Published: 2025

Journal Articles

KMT2A::AF6 fusion protein localizes to PML nuclear bodies and undergoes ATO-induced degradation: A potential novel therapeutic approach for KMT2A::AF6-rearranged Acute Myeloid Leukemia

Claudia Tregnago, Sara Perpinello, Ambra Da Ros, Maddalena Benetton, Giorgia Longo, Helmut Hanenberg, Jan-Henning Klusmann, Dirk Reinhardt, Franco Locatelli, Martina Pigazzi

Blood (2025) 146 (Supplement 1): 753.

https://doi.org/10.1182/blood-2025-753

Published: 2025

Journal Articles

Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors

Dirk Reinhardt, Lina Marie Hoffmeister, Markus Schneider, Jan-Henning Klusmann, Lisa Ostermann, Tabea Ziedrich, Kristian Juul-Dam, Nils Von Neuhoff, Caroline Augsburg, Denise Kondryn, Christel Katerkamp, Sophia Meerkamp, Naghmeh Niktoreh, Evangelia Antoniou, Helena Kerp, Katarzyna Majstrowicz, Katharina Waack

Blood (2025) 146 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2025-5174

Published: 2025

Journal Articles

TP53 mutations define a high-risk subgroup in pediatric Acute Myeloid Leukemia with distinct molecular and cytogenetic features

Stephanie Sendker, Lina Marie Hoffmeister, Nils Von Neuhoff, Jan-Henning Klusmann, Dirk Reinhardt, Markus Schneider, Evangelia Antoniou

Blood (2025) 146 (Supplement 1): 447.

https://doi.org/10.1182/blood-2025-447

Published: 2025

Journal Articles

CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

Blood blood.2025030775.

https://doi.org/10.1182/blood.2025030775

Published: 2025

Includes: Supplemental data

Journal Articles

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

Blood blood.2024027904.

https://doi.org/10.1182/blood.2024027904

Published: 2025

Includes: Supplemental data

Journal Articles

Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome

Austin C. Boucher, Wojciech Rosikiewicz, Ricky Tirtakusuma, Anitria Cotton, Madeline Niederkorn, Elvin Wagenblast, Paul G. Thomas, Yubin Ge, Jeffrey W. Taub, Jan-Henning Klusmann, John D. Crispino

Blood (2024) 144 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2024-210782

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Eva Rettinger, Martin Hutter, Birte Karschen, Evangelia Antoniou, Peter Bader, Rita Beier, Birgit Burkhardt, Ursula Creutzig, Gabriele Escherich, Jan-Henning Klusmann, Peter Lang, Naghmeh Niktoreh, Martin G. Sauer, Stephanie Sendker, Dirk Reinhardt, Katharina Waack

Blood (2024) 144 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2024-208311

Published: 2024

Journal Articles

MYC-stery of Down syndrome unraveled

Jan-Henning Klusmann

Blood (2024) 143 (25): 2566–2567.

https://doi.org/10.1182/blood.2024024595

Published: 2024

Journal Articles

TRIP13 Is a Fetal-Enriched Therapeutic Target in NUP98-JARID1A + Pediatric Non-Down Syndrome AMKL

Luca Nunzio Cifarelli, Hasan Issa, Konstantin Schuschel, Katja Menge, Lucie Gack, Christian Ihling, Andrea Sinz, Jan-Henning Klusmann, Dirk Heckl

Blood (2023) 142 (Supplement 1): 711.

https://doi.org/10.1182/blood-2023-182843

Published: 2023

Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Blood (2023) 142 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2023-188892

Published: 2023

Journal Articles

Double trouble: IRAK1/4 inhibitors in AML/MDS

Hannah J. Uckelmann, Jan-Henning Klusmann

Blood (2023) 142 (11): 945–946.

https://doi.org/10.1182/blood.2023020812

Published: 2023

Journal Articles

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Blood (2023) 141 (10): 1105–1118.

https://doi.org/10.1182/blood.2022017619

Published: 2023

Includes: Supplemental data

Journal Articles

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6224–6225.

https://doi.org/10.1182/blood-2022-157833

Published: 2022

Journal Articles

CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML

Nawid Albinger, Tobias Bexte, Leon Buchinger, Philipp Wendel, Ahmad Al-Ajami, Alec Gessner, Vinzenz Särchen, Jamal Alzubi, Sarah Mertlitz, Olaf Penack, Raj Bhayadia, Jan-Henning Klusmann, Meike Vogler, Nina Möker, Toni Cathomen, Michael A. Rieger, Katharina Imkeller, Evelyn Ullrich

Blood (2022) 140 (Supplement 1): 4558–4559.

https://doi.org/10.1182/blood-2022-169758

Published: 2022

Journal Articles

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Oriol Alejo-Valle, Karoline Weigert, Raj Bhayadia, Michelle Ng, Hasan Issa, Christoph Beyer, Stephan Emmrich, Konstantin Schuschel, Christian Ihling, Andrea Sinz, Martin Zimmermann, Claudia Wickenhauser, Marius Flasinski, Eniko Regenyi, Maurice Labuhn, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann

Blood (2022) 139 (5): 651–665.

https://doi.org/10.1182/blood.2021012231

Published: 2022

Includes: Supplemental data

Journal Articles

Myeloid Leukemia Dependencies at CTCF-Enriched Long Noncoding RNA Loci

Michelle Ng, Lonneke Verboon, Hasan Issa, Raj Bhayadia, Oriol Alejo, Dorit Borchert, Eniko Regenyi, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann

Blood (2021) 138 (Supplement 1): 500.

https://doi.org/10.1182/blood-2021-153984

Published: 2021

Journal Articles

Improved Outcome in Pediatric AML - the AML-BFM 2012 Study

Katharina Waack, Markus Schneider, PhD, Christiane Walter, MSc, Ursula Creutzig, MD, Jan-Henning Klusmann, Mareike Rasche, MD, Heidrun Boztug, Katharina Jansen, PhD, Gabriele Escherich, MD, Michael Frühwald, MD, Michael Dworzak, MD PhD, Dirk Reinhardt, MD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-139189

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group

Single-cell tracing of myeloid leukemia evolution in down syndrome reveals a latent progenitor bridging disease onset, progression and relapse

Wildtype NUP98 cooperates with NPM1c to drive oncogenic transcription

KMT2A::AF6 fusion protein localizes to PML nuclear bodies and undergoes ATO-induced degradation: A potential novel therapeutic approach for KMT2A::AF6-rearranged Acute Myeloid Leukemia

Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors

TP53 mutations define a high-risk subgroup in pediatric Acute Myeloid Leukemia with distinct molecular and cytogenetic features

CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

Multi-Pronged Effects of Cohesin Mutations in the Myeloid Leukemia of Down Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

MYC-stery of Down syndrome unraveled

TRIP13 Is a Fetal-Enriched Therapeutic Target in NUP98-JARID1A + Pediatric Non-Down Syndrome AMKL

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Double trouble: IRAK1/4 inhibitors in AML/MDS

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Myeloid Leukemia Dependencies at CTCF-Enriched Long Noncoding RNA Loci

Improved Outcome in Pediatric AML - the AML-BFM 2012 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only